Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway
{{output}}
Background: The use of systemic anti-cancer treatment (SACT) at the end of life (EOL) is controversial. The evidence and detailed description of the dynamics of its use are deficient, especially after the introduction of targeted... ...
